ResearcherVanderbilt University Medical CenterNo recent work listed

Matthew E. Bechard

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7329-5186; OpenAlex author ID A5067989289. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 2

Aminopyridine analogs selectively target metastatic pancreatic cancer. First author DOI 10.1038/s41388-022-02183-3 ↗
Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases. Co-author DOI 10.1038/s41388-018-0346-5 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Oliver Gene McDonald · 2 shared papers, 2018–2022 · strength 0.25
- Paper Aminopyridine analogs selectively target metastatic pancreatic cancer. DOI 10.1038/s41388-022-02183-3 ↗
- Paper Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases. DOI 10.1038/s41388-018-0346-5 ↗
Rana V. Smalling · 1 shared paper, 2022 · strength 0.16
- Paper Aminopyridine analogs selectively target metastatic pancreatic cancer. DOI 10.1038/s41388-022-02183-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.